Want to see IN:PAR full AI Analyst Report?
PAR Stock Chart & Stats
₹100.93
-₹2.28(-1.11%)
At close: 4:00 PM EST
₹100.93
-₹2.28(-1.11%)
Day’s Range― - ―
52-Week Range₹78.05 - ₹122.43
Previous CloseN/A
Volume42.53K
Average Volume (3M)31.06K
Market Cap
₹1.29B
Enterprise Value₹748.79M
Total Cash (Recent Filing)₹418.43M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)9.9
Beta1.00
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.65
Shares Outstanding12,304,636
10 Day Avg. Volume60,109
30 Day Avg. Volume31,062
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero-debt Balance SheetA zero-debt balance sheet materially reduces financial risk and provides durable flexibility. Over the next 2-6 months this strengthens the company’s ability to fund working capital, pursue organic investments or small M&A without refinancing risk, and better withstand industry cyclicality.
Solid Profitability And ReturnsMid-teens net margins and a double-digit ROE indicate the core business converts revenue into earnings efficiently. This durability supports internal funding for R&D and capacity, underpins cash generation, and signals competitive pricing or cost advantages in its specialty/generic drug segment.
Positive Free Cash Flow GenerationConsistent positive free cash flow across periods shows the business generates surplus cash after capex, a durable source for reinvestment, deleveraging (if desired), or shareholder returns. Even with timing swings, persistent free cash flow strengthens long-term financial resilience.
Bears Say
Inconsistent Revenue GrowthVariable top-line trends reduce predictability of future earnings and complicate capacity planning. Over a 2-6 month horizon, inconsistent organic growth raises questions about sustained market demand, product mix shifts, or reliance on episodic contract wins rather than steady recurring revenues.
Margin Volatility And CompressionVolatile and compressed margins suggest exposure to input cost swings, pricing pressure, or changing product mix. Persisting margin instability can erode long-term profitability, limit reinvestment capacity, and increase sensitivity to competitive or regulatory cost shifts over the medium term.
Uneven Cash ConversionIrregular conversion of earnings to cash, driven by working-capital timing, makes free cash flow less predictable. This can constrain capital allocation decisions, raise short-term liquidity risk in adverse scenarios, and complicate durable plans for dividends, capex, or strategic investments.
Par Drugs and Chemicals Limited News
PAR FAQ
What was Par Drugs and Chemicals Limited’s price range in the past 12 months?
Par Drugs and Chemicals Limited lowest stock price was ₹78.05 and its highest was ₹122.43 in the past 12 months.
What is Par Drugs and Chemicals Limited’s market cap?
Par Drugs and Chemicals Limited’s market cap is ₹1.29B.
When is Par Drugs and Chemicals Limited’s upcoming earnings report date?
Par Drugs and Chemicals Limited’s upcoming earnings report date is Jul 31, 2026 which is in 11 days.
How were Par Drugs and Chemicals Limited’s earnings last quarter?
Par Drugs and Chemicals Limited released its earnings results on May 14, 2026. The company reported ₹0.69 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.69.
Is Par Drugs and Chemicals Limited overvalued?
According to Wall Street analysts Par Drugs and Chemicals Limited’s price is currently Overvalued.
Does Par Drugs and Chemicals Limited pay dividends?
Par Drugs and Chemicals Limited pays a Notavailable dividend of ₹1.25 which represents an annual dividend yield of N/A. See more information on Par Drugs and Chemicals Limited dividends here
What is Par Drugs and Chemicals Limited’s EPS estimate?
Par Drugs and Chemicals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Par Drugs and Chemicals Limited have?
Par Drugs and Chemicals Limited has 12,304,636 shares outstanding.
What happened to Par Drugs and Chemicals Limited’s price movement after its last earnings report?
Par Drugs and Chemicals Limited reported an EPS of ₹0.69 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.398%.
Which hedge fund is a major shareholder of Par Drugs and Chemicals Limited?
Currently, no hedge funds are holding shares in IN:PAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Par Drugs and Chemicals Limited
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds, such as magnesium salts, dried aluminum hydroxide gel, sodium aluminum silicate, precipitated silica, magnesium silicate, colloidal silicon dioxide, sucralfate USP, as well as various amorphous and custom-blended formulations. The company also extends its market presence through international exports. Founded in 1982, Par Drugs and Chemicals Limited is headquartered in Vadodara, India.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Brooks Laboratories Limited
―
Vivimed Labs Limited
―